Glass House Brands (GLAS) Other financing activities (2020 - 2026)
Glass House Brands' (GLAS) quarterly Other financing activities came in at -$212000.0 in Q1 2026, down 12.17% on a QoQ basis from -$189000.0 in Q4 2025.
Glass House Brands (GLAS) Other financing activities (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Other financing activities data on file, last reported at -$212000.0 in Q1 2026.
- On a quarterly basis, Other financing activities changed N/A year-over-year to -$212000.0 in Q1 2026; TTM through Mar 2026 was -$432000.0, a N/A change from a year earlier, with the FY2025 full-year figure at -$342000.0, down 213.76% from the prior year.
- Other financing activities for Q1 2026 stood at -$212000.0, down from -$189000.0 in the prior quarter.
- Over the last five years, Other financing activities for GLAS reached as high as $54066.8 billion in Q4 2022 and fell as low as -$212000.0 in Q1 2026.
- Historically, Other financing activities has averaged $4505.6 billion across 5 years, with a median of -$37952.0 in 2023.
- Across the five-year window, Other financing activities jumped 42650205.21% in 2022 and tumbled 146.36% in 2023, its largest moves.
- Year by year, Other financing activities stood at $54066.8 billion in 2022, then plunged by 100.0% to $136682.0 in 2023, then tumbled by 122.68% to -$31000.0 in 2024, then plunged by 509.68% to -$189000.0 in 2025, then retreated by 12.17% to -$212000.0 in 2026.
- Per Business Quant data, the three most recent Other financing activities figures were -$212000.0 in Q1 2026, -$189000.0 in Q4 2025, and -$31000.0 in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -212,000.00 |
| Mar 31, 2026 | -212,000.00 |
| Dec 31, 2025 | -189,000.00 |
| Dec 31, 2025 | -189,000.00 |
| Sep 30, 2024 | -31,000.00 |
| Sep 30, 2024 | -31,000.00 |
| Jun 30, 2024 | -31,000.00 |
| Jun 30, 2024 | -31,000.00 |
| Mar 31, 2024 | -47,000.00 |
| Mar 31, 2024 | -47,000.00 |
| Dec 31, 2023 | 136,682.00 |
| Dec 31, 2023 | 136,682.00 |
| Sep 30, 2023 | -45,470.00 |
| Sep 30, 2023 | -45,470.00 |
| Jun 30, 2023 | -44,904.00 |
| Jun 30, 2023 | -44,904.00 |
| Mar 31, 2023 | -46,308.00 |
| Mar 31, 2023 | -46,308.00 |
| Dec 31, 2022 | 54,066.83 Bn |
| Dec 31, 2022 | 54,066.83 Bn |